Shares of Novavax Inc. NVAX rallied 2.15% to $9.52 Tuesday, on what proved to be an all-around great trading session for the ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Novavax Inc. closed 60.94% below its 52-week high of $23.86, which the company reached on June 6th.

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%.

The most recent trading session ended with Novavax (NVAX) standing at $9.34, reflecting a +1.3% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 1.46%.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates.

I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 ...

SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.55 which represents a slight increase of $0.72 or 8.15% from the prior close of $8.83. The stock opened at $8.82 and touched a low of ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...